Alzheimer’s Vaccine Approved in 2nd Phase of Human Trials

Second article published in the journal Nature Aging, an experimental Alzheimer’s vaccine developed by Axon Neuroscience, was approved in its second phase of human trials, conducted over 24 months. The substance was shown to be safe and produced an immune response to certain disease factors.

Of a total of 193 participants, 117 received 11 doses of the so-called AADvac1, based on the peptide, while the rest, in a double-blind randomized study, took a placebo. Those immunized showed high levels of IgG antibody action against abnormal agglomerations of tau proteins, harmful to the brain.

Substance has been shown to be safe in tests.
Substance has been shown to be safe in tests.Source: Freepik

The last trial suggested a slower neurodegeneration in the first group, reduced by about 30% when compared to the other group. At this stage, it is not yet known whether the vaccine makes it possible to reverse the condition.

Petr Novak, research leader, declared in an interview with MedPage Today : “As far as I know, this is the first time that a tau-targeted immunotherapy has shown clear evidence of impact on the neurodegenerative process and a strong indication of clinical effect in patients with a confirmed Alzheimer’s disease biomarker profile.”

caution and hope

Despite the promising signs, highlights the team, it is still too early to celebrate. This is because, in the entire sample, no significant effect was found in functional cognitive tests, as well as the results, in addition to exclusively attesting to the absence of adverse effects, are related to a small number of individuals, especially those affected by Alzheimer’s linked to tau . More research, then, is needed.

In any case, in a specific subset, 109 patients were more likely to be positive for the evaluated biomarkers, and this fact is important. In addition, doubts are common in the search for something to help around 35.6 million people worldwide affected by the disease, according to estimates by the World Health Organization.

More research is needed.
More research is needed.Source: Freepik

Finally, adjustments will be necessary for the multiplicity tests, as some limitations were not pre-specified in the study protocol. “These results must, therefore, be interpreted with caution and will require confirmation in future clinical development,” the scientists ponder.

Previous post iPhone app lets user browse classic iOS 4 from 2010
Next post Samsung Galaxy S21 will come without charger and phone in box